Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List

Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.

Forbidden city, Beijing
China Opens Arms To Faster Launches Of Rare Disease Treatments • Source: Shutterstock

Unlike previous rounds of fast track approval review designations in China, in which oncology drugs took the lead, this time orphan drugs are shining.

The latest list of selected products released March 28 by China’s National Medical Products Administration (NMPA) appears to have a...

More from Rare Diseases

More from Pink Sheet

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By 

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."